FDA Approves Degevma, a Biosimilar to Xgeva, for Bone Complications and Tumors

The U.S. Food and Drug Administration (FDA) has approved Degevma (denosumab-adet), a biosimilar to Xgeva (denosumab), for all its indications. These include preventing bone complications in adults with advanced cancer that has spread to the bone, treating adults and skeletally mature adolescents with giant cell tumor of bone, and treating hypercalcemia of malignancy.